Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Giant warts in a kidney transplant patient: regression with sirolimus.

Kostaki M, Venetz JP, Nseir G, Meylan P, Sahli R, Pascual M, Laffitte E.

Br J Dermatol. 2010 May;162(5):1148-50. doi: 10.1111/j.1365-2133.2010.09687.x. Epub 2010 Mar 12. No abstract available.

PMID:
20346038
2.

Sirolimus-based immunosuppression for treatment of cutaneous warts in kidney transplant recipients.

Shahidi S, Moeinzadeh F, Mohammadi M, Gholamrezaei A.

Iran J Kidney Dis. 2011 Sep;5(5):351-3.

3.

Sirolimus and regression of Kaposi's sarcoma in immunosuppressed transplant patient.

Pranteda G, Feliziani G, Grimaldi M, Paleologo G, Pranteda G, Melotti F, Camplone G.

J Eur Acad Dermatol Venereol. 2008 Aug;22(8):1022-3. doi: 10.1111/j.1468-3083.2007.02536.x. Epub 2008 Jan 10. No abstract available.

PMID:
18194240
4.

Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases.

Mathis AS, Shah NK, Friedman GS.

Transplant Proc. 2004 Nov;36(9):2708-9.

PMID:
15621130
5.

Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome.

Levi Z, Hazazi R, Kedar-Barnes I, Hodak E, Gal E, Mor E, Niv Y, Winkler J.

Am J Transplant. 2007 Feb;7(2):476-9. Epub 2007 Jan 4.

6.

Conversion to rapamycin in a renal transplant patient with von Hippel-Lindau disease: encouraging results-a case report.

Henriquez F, Gallego R, Oliva E, Silva D, Vega N.

Transplant Proc. 2008 Nov;40(9):3115-6. doi: 10.1016/j.transproceed.2008.08.086.

PMID:
19010210
7.

Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.

Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.

Clin Transplant. 2004;18 Suppl 12:61-6.

PMID:
15217410
8.

Sirolimus for Kaposi's sarcoma.

Wasywich CA, Croxson MC, van Doornum GJ, Coverdale HA, Ruygrok PN.

J Heart Lung Transplant. 2006 Jun;25(6):726-9.

PMID:
16730579
9.

Sirolimus inhibits oxidative burst activity in transplant recipients.

Gee I, Trull AK, Charman SC, Alexander GJ.

Transplantation. 2003 Dec 27;76(12):1766-8.

PMID:
14688530
10.

Immunosuppressive drugs and the risk of cancer after organ transplantation.

Dantal J, Soulillou JP.

N Engl J Med. 2005 Mar 31;352(13):1371-3. No abstract available.

PMID:
15800234
11.

A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.

Yilmaz R, Akoglu H, Kirkpantur A, Kilickap S, Arici M, Altun B, Aki T, Erdem Y, Yasavul U, Turgan C.

Ren Fail. 2007;29(1):103-5.

PMID:
17365918
12.

Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.

Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.

Transplant Proc. 2009 Sep;41(7):2789-93. doi: 10.1016/j.transproceed.2009.07.094.

PMID:
19765436
13.

Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus.

Mohsin N, Budruddin M, Pakkyara A, Darweesh A, Nayyer M, Amitabh J, Daar AS.

Exp Clin Transplant. 2005 Dec;3(2):366-9.

14.

Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus.

Hricik DE, Knauss TC, Bodziak KA, Weigel K, Rodriguez V, Seaman D, Siegel C, Valente J, Schulak JA.

Transplantation. 2003 Sep 27;76(6):938-42.

PMID:
14508357
15.

Sirolimus for solid organ transplantation in children.

Gupta P, Kaufman S, Fishbein TM.

Pediatr Transplant. 2005 Jun;9(3):269-76.

PMID:
15910380
16.

Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration.

Saurina A, Campistol JM, Lario S, Oppenheimer F, Diekmann F.

Transplant Proc. 2007 Sep;39(7):2138-41.

PMID:
17889117
17.

Regression of post-transplant Kaposi's sarcoma using sirolimus.

Kolhe N, Mamode N, Van der Walt J, Pattison J.

Int J Clin Pract. 2006 Nov;60(11):1509-12.

PMID:
16787440
18.

Choice of immunosuppressants and the risk of warts in renal transplant recipients.

Dicle O, Parmaksizoglu B, Gurkan A, Tuncer M, Demirbas A, Yilmaz E.

Acta Derm Venereol. 2008;88(3):294-5. doi: 10.2340/00015555-0411. No abstract available.

19.
20.

Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus.

Mohsin N, Budruddin M, Kamble P, Khalil M, Pakkyarra A, Jha A, Mohammed E, Ahmed H, Ahmed J, Thomas S, Campistol JM, Daar A.

Transplant Proc. 2007 May;39(4):1267-71.

PMID:
17524950

Supplemental Content

Support Center